#### **Technical Data Sheet**

# InVivoMAb anti-mouse TIM-3 (CD366)



# **Lot Specific Information**

Lot Number:Lot Specific\*Volume:Lot Specific\*

Concentration: Lot Specific\* (generally 4 to 11 mg/ml) \*

Total Protein: Lot Specific\*

\*This information will be noted on the certificate of analysis that ships with this product.

#### **Product Information**

**Reported Applications:** 

 Catalog Number:
 BE0275

 Clone:
 B8.2C12

 Isotype:
 Rat IgG1, к

Recommended Isotype Control(s): InVivoMAb rat IgG1 isotype control, anti-horseradish peroxidase

Recommended Dilution Buffer: InVivoPure pH 7.0 Dilution Buffer

**Immunogen:** Mouse Tim-3 protein/Freund adjuvant

in vivo TIM-3 neutralization in vitro TIM-3 blocking

Flow cytometry
PBS, pH 7.0

Contains no stabilizers or preservatives

**Endotoxin:** <2EU/mg (<0.002EU/μg)

Determined by LAL gel clotting assay

Purity: >95%

Determined by SDS-PAGE

Sterility: 0.2 µM filtered

**Production:** Purified from tissue culture supernatant in an animal free facility

Purification:Protein GRRID:AB\_2687798Molecular Weight:150 kDa

#### **Description**

The B8.2C12 monoclonal antibody reacts with mouse TIM-3 (T cell immunoglobulin and mucin domain-3) also known as CD366. This antibody binds to the BALB/c allele of TIM-3 while reactivity to the C57Bl/6 allele is significantly weaker. TIM-3 is a 60 kDa member of the TIM family of immune checkpoint receptors and exists as a type I transmembrane glycoprotein with a mucin-like domain in its extracellular portion and a tyrosine phosphorylation motif in its cytoplasmic portion. TIM-3 is specifically expressed at high levels on the surface of Th1 lymphocytes whereas Th2 lymphocytes express TIM-1 and TIM-2. TIM-3 activation occurs via binding to the cell-associated C-type lectin galectin-9. Upon binding TIM-3 induces apoptosis of Th1 cells. Inhibition of TIM-3 signaling in mice has been shown to exacerbate experimental autoimmune encephalomyelitis, promote IFNγ production and Th1 cell proliferation. Tim-3 has also been shown to be required for the induction of tolerance, as both TIM-3 knockout animals and mice treated with TIM-3-Ig fusion protein display defects in the induction of antigen-specific tolerance. Additionally, TIM-3 signaling is currently being explored as a cancer immunotherapy target as CD8 T cells which express both TIM-3 and PD-1 exhibit greater defects in both cell-cycle progression and effector cytokine production than cells that express PD-1 alone.

## **Shelf-life and Storage**

Store at the stock concentration at 4°C. Do not freeze.

# **Protocol Information**

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

# **Application References**

For a complete list of references, visit https://bxcell.com/product/invivomab-anti-mouse-cd366-tim-3/#references or scan the QR code below.

### Bio X Cell, Inc.

bxcell.com

1.866.787.3444

## customerservice@bxcell.com

Conditions: For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.



Bio X Cell, Inc.

bxcell.com 1.866.787.3444

customerservice@bxcell.com

Conditions: For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.